Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication

Journal of Virology

Volumn 73, Issue 12, 1999, Pages 10000-10009

  Berthoux, Lionel ^a,b   Péchoux, Christine ^a   Darlix, Jean Luc ^a  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; NUCLEOCAPSID PROTEIN; VIRUS DNA; ZINC FINGER PROTEIN;

ARTICLE; DNA SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS INHIBITION; VIRUS MORPHOLOGY; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

EID: 0344671562     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.12.10000-10009.1999     Document Type: Article

References (51)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Aldovini, A., and R. A. Young. 1990. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J. Virol. 64:1920-1926.
3. Auxilien, S., G. Keith, S. F. J. Le Grice, and J.-L. Darlix. 1999. Role of post-transcriptional modifications of primer tRNALys.3 in the fidelity and efficacy of plus strand DNA transfer during HIV-1 reverse transcription. J. Biol. Chem. 274:4412-4420.
4. Berthoux, L., C. Péchoux, M. Ottmann, G. Morel, and J. L. Darlix. 1997. Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis. J. Virol. 71:6973-6981.
5. Chen, C., and H. Okayama. 1987. High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752.
6. Clavel, F., and P. Charneau. 1994. Fusion from without directed by human immunodeficiency virus particles. J. Virol. 68:1179-1185.
7. Collin, M., and S. Gordon. 1994. The kinetics of human immunodeficiency virus reverse transcription are slower in primary human macrophages than in lymphoid cell line. Virology 200:114-120.
8. Darlix, J.-L. Unpublished results.
9. Darlix, J.-L., C. Gabus, M. T. Nugeyre, F. Clavel, and F. Barré-Sinoussi. 1990. Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. J. Mol. Biol. 216:689-699.
10. Darlix, J.-L., M. Lapadat-Tapolsky, H. de Rocquigny, and B. P. Roques. 1995. First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. J. Mol. Biol. 254:523-537.
11. de Guzman, R., Z. Rong Wu, C. C. Stalling, L. Pappalardo, P. N. Borer, and M. F. Summers. 1998. Structure of the HIV-1 nucleocapsid protein bound to the SL3 PSI-RNA recognition element. Science 279:384-388.
12. Dorfman, T., J. Luban, S. P. Goff, W. A. Haseltine, and H. G. Göttlinger. 1993. Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type-1 nucleocapsid protein. J. Virol. 67:6159-6169.
13. Finzi, D., and R. F. Siliciano. 1998. Viral dynamics in HIV-1 infection. Cell 93:665-671.
14. Freed, E. O. 1998. HIV-1 Gag proteins: diverse functions in the virus life cycle. Virology 251:1-15.
15. Fu, W., R. J. Gorelick, and A. Rein. 1994. Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions. J. Virol. 68:5013-5018.
16. Gallay, P., T. Hope, T. Chin, and D. Trono. 1997. HIV-1 infection of non-dividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc. Natl. Acad. Sci. USA 94:9825-9830.
17. Gallay, P., S. Swingler, J. Song, F. Bushman, and D. Trono. 1995. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell 83:569-576.
18. Gervaix, A., D. West, L. M. Leoni, D. D. Richman, F. Wong-Staal, and J. Corbeil. 1997. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc. Natl. Acad. Sci. USA 94:4653-4658.
19. Goff, S., P. Traktman, and D. Baltimore. 1981. Isolation and properties of Moloney murine leukemia virus mutants: use of rapid assay for release of virion reverse transcriptase. J. Virol. 38:239-248.
20. Günthard, H. F., J. K. Wong, C. C. Ignacio, J. C. Guatelli, N. L. Riggs, D. V. Havlir, and D. D. Richman. 1998. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72:2422-2428.
21. Huang, M., A. Maynard, J. A. Turpin, L. Graham, G. M. Janini, D. G. Covell, and W. G. Rice. 1988. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. J. Med. Chem. 41:1371-1381.
22. Korber, B. T., K. J. Kunstman, B. K. Patterson, M. Furtado, M. M. McEvilly, R. Levy, and S. M. Wolinsky. 1994. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J. Virol. 68:7467-7481.
23. Lamarre, D., G. Croteau, E. Wardrop, L. Bourgon, D. Thibeault, C. Clouette, M. Vaillancourt, E. Cohen, C. Pargellis, C. Yoakim, and P. C. Anderson. 1997. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents. Chemother. 41:965-971.
24. Larder, B. A. 1995. Viral resistance and the selection of antiretroviral recombination. J. AIDS Hum. Retroviruses 10:S28-S33.
25. Lener, D., V. Tanchou, B. P. Roques, S. F. J. Le Grice, and J.-L. Darlix. 1998. Involvement of HIV-1 nucleocapsid protein in the recruitment of reverse transcriptase into nucleoprotein complexes formed in vitro. J. Biol. Chem. 273:33781-33786.
26. + cells. J. Gen. Virol. 74:2077-2083.
27. Meric, C., and S. P. Goff. 1989. Characterization of Moloney murine leukemia virus mutants with single-amino-acid substitutions in the Cys-His box of the nucleocapsid protein. J. Virol. 63:1558-1568.
28. Morellet, N., H. de Rocquigny, Y. Mely, N. Jullian, H. Demene, M. Ottmann, D. Gerard, J. L. Darlix, M. C. Fournie-Zaluski, and B. P. Roques. 1994. Conformational behaviour of the active and inactive forms of the nucleocapsid NCp7 of HIV-1 studied by 1H NMR. J. Mol. Biol. 235:287-301.
29. 1H NMR. EMBO J. 11:3059-3065.
30. Ottmann, M., C. Gabus, and J. L. Darlix. 1995. The central globular domain of the nucleocapsid protein of human immunodeficiency virus type 1 is critical for virion structure and infectivity. J. Virol. 69:1778-84.
31. Page, K. A., N. R. Landau, and D. R. Littman. 1990. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol. 64:5270-5276.
32. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Oreinstein, D. P. Kotler, and A. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358.
33. Péchoux, C., and G. Morel. 1993. In situ hybridization in semithin sections, p. 101-138. In G. Morel (ed.), Hybridization techniques for electron microscopy. CRC Press, Inc., Boca Raton, Fla.
34. Pettit, S. C., M. D. Moody, R. S. Wehbie, A. H. Kaplan, P. V. Nantermet, C. A. Klein, and R. Swanstrom. 1994. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68:8017-8027.
35. Poon, D. T. K., J. Wu, and A. Aldovini. 1996. Charged amino acid residues of human immunodeficiency virus type 1 nucleocapsid p7 protein involved in RNA packaging and infectivity. J. Virol. 70:6607-6616.
36. Rein, A., L. E. Henderson, and J. G. Levin. 1998. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem. Sci. 23:297-301.
37. Rice, W. G., D. C. Baker, C. A. Schaeffer, L. Graham, M. Bu, S. Terpening, D. Clanton, R. Schultz, J. P. Bader, R. W. Buckheit Jr, L. Field, P. K. Singh, and J. A. Turpin. 1997. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob. Agents Chemother. 41:419-426.
38. Rice, W. G., C. A. Schaeffer, B. Harten, F. Villinger, T. L. South, M. F. Summers, L. E. Henderson, J. W. Bess, Jr., L. O. Arthur, J. S. McDougal, S. L. Orloff, J. Mendeleyev, and E. Kun. 1993. Inhibition of HIV-1 infectivity by C-nitroso compounds. Nature 361:473-475.
39. Rice, W. G., J. G. Supko, L. Malspeis, R. W. Buckheit, Jr., D. Clanton, M. Bu, L. Graham, C. A. Schaeffer, J. A. Turpin, J. Domagala, R. Cogliotti, J. P. Bader, S. M. Halliday, L. Coren, R. C. Sower II, L. O. Arthur, and L. E. Henderson. 1995. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270:1194-1197.
40. Rice, W. G., J. A. Turpin, M. Huang, D. Clanton, R. W. Buckheit, Jr., D. G. Covell, A. Wallqvist, N. B. McDonnall, R. N. DeGuzman, M. F. Summers, L. Zalkow, J. P. Bader, R. D. Haugwitz, and E. A. Sausville. 1997. Azodicar-bonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat. Med. 3:341-345.
41. Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R Higushi, G. T. Horn, K. B. Mullis, and H. A. Erlich. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487-491.
42. Smith, S. D., M. Shatsky, P. S. Cohen, R. Warnke, M. P. Link, and B. E. Glader. 1984. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res. 44:5657-5660.
43. South, T. L., P. R. Blake, D. R. Hare, and M. F. Summers. 1991. C-terminal retroviral-type zinc finger domain from the HIV-1 nucleocapsid protein is structurally similar to the N-terminal zinc finger domain. Biochemistry 30: 6342-6349.
44. Tanchou, V., D. Décimo, C. Péchoux, D. Lener, V. Rogemond, L. Berthoux, M. Ottmann, and J.-L. Darlix. 1998. Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication. J. Virol. 72:4442-4447.
45. Tummino, P. J., J. D. Scholten, P. J. Harvey, T. P. Holler, L. Maloney, R. Gogliotti, J. Domagala, and D. Hupe. 1996. The in vitro ejection of zinc from human immunodeficiency virus type 1 nucleocapsid protein by disulfide benzamides with cellular anti-HIV activity. Proc. Natl. Acad. Sci. USA 93: 969-973.
46. Turpin, J. A., Y. Song, J. K. Inman, M. Huang, A. Wallqvist, A. Maynard, D. G. Covell, W. G. Rice, and E. Appella. 1999. Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. J. Med. Chem. 42:67-86.
47. Turpin, J. A., S. J. Terpening, C. A. Schaeffer, G. Yu, C. J. Glover, R. L. Felsted, E. A. Sausville, and W. G. Rice. 1996. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of Gag precursors and result in the release of noninfectious viral particles. J. Virol. 70:6180-6189.
48. Vandevelde, M., J. C. Schmit, M. Witvrouw, S. Sprecher, E. De Clerq, and J.-P. Tassignon. 1996. ADA, a potential anti-HIV drug. AIDS Res. Hum. Retroviruses 12:567-568.
49. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
50. Zhang, Y., and E. Barklis. 1997. Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation. J. Virol. 71:6765-6776.
51. Zhang, Y.-M., H. Imamichi, T. Imamichi, H. Clifford Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.